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Objective: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-
treatment biochemical and virological response rates with peginterferon a-2a with or without lamivudine
were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment
responses was investigated.
Methods: Multivariate analyses were performed using available data from 518 patients treated with
peginterferon a-2a with or without lamivudine, or with lamivudine alone. A post-treatment response was
defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of ,20 000
copies/ml.
Results: In logistic regression analyses across all treatment arms, peginterferon a-2a (with or without
lamivudine) therapy, younger age, female gender, high baseline ALT, low baseline HBV DNA and HBV
genotype were identified as significant predictors of combined response at 24 weeks post-treatment. In the
peginterferon a-2a and lamivudine monotherapy arms, patients with genotypes B or C had a higher chance
of response than genotype D infected patients (p,0.001), the latter responding better to the combination than
to peginterferon a-2a monotherapy (p = 0.015). At 1 year post-treatment, response rates by intention-to-treat
analysis were 19.2% for the peginterferon a-2a, 19.0% for the combination, and 10.0% for the lamivudine
groups, with genotypes B or C associated with a sustained combined response to peginterferon a-2a with or
without lamivudine therapy.
Conclusions: Baseline ALT and HBV DNA levels, patient age, gender, and infecting HBV genotype
significantly influenced combined response at 24 weeks post-treatment, in patients treated with peginterferon
a-2a and/or lamivudine. At 1 year post-treatment HBV genotype was significantly predictive of efficacy for
patients treated with peginterferon a-2a with or without lamivudine.
C
hronic hepatitis B virus (HBV) infection continues to be a
major global health problem with more than 400 million
cases worldwide and is a significant cause of cirrhosis and
hepatocellular carcinoma.1 Hepatitis B e antigen (HBeAg)-
negative chronic hepatitis B (CHB) represents the late phase of
the infection where the HBV population is predominantly made
up of HBV precore/basic core promoter variants that reduce or
abolish the expression of HBeAg.2 3 Spontaneous sustained
remissions are rare in patients with HBeAg-negative CHB and
the disease is characterised by persistent viral replication,
progressive liver damage and early development of cirrhosis.4–6
HBeAg-negative CHB is particularly prevalent in the
Mediterranean region and Asia. Nevertheless, recent studies
indicate that HBeAg-negative disease may be more common
than previously suspected and that its prevalence is increasing
worldwide.2 3
Until recently, conventional interferon a and lamivudine
were the only drugs specifically licensed for the treatment of
CHB. However, in patients with HBeAg-negative CHB, both
drugs are associated with high rates of relapse upon treatment
discontinuation and poor sustained response rates.7–11
Furthermore, conventional interferon a has a suboptimal
pharmacokinetic profile that necessitates an inconvenient
dosing regimen (three times weekly). Lamivudine is hindered
by the development of drug resistance, which increases with
prolonged use.12 13 In the past few years, the nucleotide
analogue, adefovir, has been approved as a treatment option
for CHB, although continuous administration is required in
patients with HBeAg-negative disease due to rapid biochemical,
virological, and histological rebound upon adefovir withdra-
wal.14 Continuous adefovir therapy is also associated with
increased drug resistance, albeit at a lower cumulative rate than
lamivudine.15 Peginterferon a-2a, which was also recently
approved for the treatment of CHB, has been shown to provide
significantly higher post-treatment response rates compared
with lamivudine in patients with HBeAg-negative CHB.16
Peginterferon a-2a, which has dual immunomodulatory and
antiviral activity, has also proved more effective than both
conventional interferon and lamivudine in patients with
HBeAg-positive disease.17 18
To date, investigations of predictors of response have
generally focused on patients with HBeAg-positive CHB. In
patients with this phase of the disease, low serum HBV DNA
levels and high serum alanine aminotransferase (ALT) levels at
baseline have been shown to be independently associated with
improved responses to conventional interferon a.19–22 Likewise,
in patients receiving lamivudine, high baseline ALT was
identified as the most important predictor of HBeAg loss by
multivariate modelling.23 Higher rates of HBeAg clearance after
Abbreviations: ALT, alanine aminotransferase; CHB, chronic hepatitis B;
HAI, Histological Activity Index; HBeAg, hepatitis B e antigen; HBsAg,
hepatitis B s antigen; HBV, hepatitis B virus; ITT, intention-to-treat; ULN,
upper limit of normal
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conventional interferon a therapy have been reported for Asian
patients infected with HBV genotype B compared with
genotype C.22 24 However, HBV genotype seems not to influence
HBeAg responses to lamivudine, at least in Chinese patients.25
At present, no detailed analysis of predictors of response has
been performed in patients with HBeAg-negative CHB.
Accordingly, in the current study we report predictors of
combined response to peginterferon a-2a monotherapy, pegin-
terferon a-2a plus lamivudine combination therapy, and
lamivudine monotherapy using data from a large multi-
national, randomised trial involving 537 patients with
HBeAg-negative disease.16
METHODS
The patients and results of the study of peginterferon a-2a
monotherapy versus peginterferon a-2a plus lamivudine versus
lamivudine monotherapy in HBeAg-negative CHB have been
described elsewhere.16 All patients gave written informed
consent. All patients were positive for hepatitis B s antigen
(HBsAg) and anti-HBe antibody, but negative for HBeAg. Entry
criteria included an HBV DNA level of.100 000 copies/ml and an
ALT level .1 times but (10 times the upper limit of normal
(ULN; 30 IU/l in this study). All included patients had CHB status
confirmed by liver biopsy within the 12 months prior to
randomisation. Previous treatment for CHB was allowed, but
not within the 6 months prior to the study. Patients were
randomly assigned in a 1:1:1 ratio to receive 48 weeks of either
peginterferon a-2a (40KD; PEGASYS, Roche, Basel, Switzerland)
180 mg once weekly plus oral placebo once daily; peginterferon a-
2a 180 mg once weekly plus lamivudine 100 mg once daily
(Epivir-HBV/Zeffix, GlaxoSmithKline, Greenford, UK); or lami-
vudine 100 mg once daily. The co-primary endpoints of the study
were ALT normalisation and an HBV DNA level of ,20 000
copies/ml, measured at 24 weeks post-treatment (week 72). All
study centres involved in the initial clinical trial were invited to
participate in a roll-over long-term observational study to assess
the durability of response. For this analysis, patients were
assessed 1 year after the end of treatment using the same efficacy
measures as at 24 weeks post-treatment.
Virological, biochemical and histological measurements
Serum HBV DNA was measured at a central laboratory using
the COBAS AMPLICOR HBV MONITOR (Roche Diagnostics,
Branchburg, NJ, USA). Serum ALT was measured at local
laboratories in accordance with common standardised proce-
dures. Baseline biopsy specimens were scored using the
modified Histological Activity Index (HAI) score26 by an
independent histopathologist who was unaware of the patient’s
treatment assignment.
Definition of response and relapse
In the present analyses, a post-treatment combined response was
defined as both ALT normalisation and an HBV DNA level of
,20 000 copies/ml, 24 weeks after the end of the treatment
period. Patients with missing values at 24 weeks post-treatment
were considered as treatment failures (ie, no combined response).
A sustained virological response was defined as an HBV DNA
level of ,20 000 copies/ml at the end of treatment and at
24 weeks post-treatment; post-treatment virological relapse was
defined as HBV DNA level of ,20 000 copies/ml at the end of
treatment but .20 000 copies/ml at 24 weeks post-treatment.
Statistics
Multiple logistic regression with prospectively defined covari-
ates of interest was used to determine pre-treatment factors
predictive of a combined response at 24 weeks post-treatment.
We did not formally use any of the following automatic
selection procedures: forward-entry, backward elimination,
stepwise or best-subset selection. The predictors included in
the model were all pre-specified, except that ‘‘region’’ was
eliminated because of the confounding with genotype. The
parameters of the logistic regression were fitted with the
maximum likelihood procedure, and all statistical tests were
Wald tests.
The pre-treatment factors included were age, gender,
genotype, ethnicity, body weight, HAI score, serum ALT
(screening and baseline) and serum HBV DNA (baseline).
Gender, genotype and ethnicity were included as categorical
variables; age, body weight, HAI score, serum ALT and serum
HBV DNA were included as continuous variables. Those pre-
treatment factors found to be significant in the overall logistic
regression model were assessed in stratified analyses to show
rates of response across different categories of these character-
istics. Additional comparative logistic regression analyses were
performed to investigate pre-treatment and on-treatment
factors associated with sustained virological response and
post-treatment virological relapse. The statistical analysis soft-
ware used was SAS version 8.0 (SAS Institute, Cary, NC).
RESULTS
Effect of pre-treatment factors on combined response at
24 weeks post-treatment (data from the initial study)
As previously reported,16 the percentage of patients achieving a
combined response at 24 weeks post-treatment was signifi-
cantly higher with peginterferon a-2a monotherapy (36%; 63/
177) or peginterferon a-2a plus lamivudine combination
therapy (38%; 68/179) than with lamivudine monotherapy
(23%; 42/181; p = 0.011 and p = 0.002, respectively).
Of the 537 patients analysed using the intent-to-treat
principle in the original study,16 only those of Asian or
Caucasian origin and singularly infected with HBV genotype
A, B, C or D were included in the overall logistic regression
analysis (n = 518); 19 patients were excluded as they were of
non-Caucasian/non-Asian origin and/or were infected with a
mixed HBV genotype population or HBV genotypes E, G or H.
Multivariate analyses
In the initial multivariate analysis of individual pre-treatment
factors, baseline HBV DNA, baseline ALT, treatment arm, age
and gender were significant predictors of a combined response
in patients receiving peginterferon a-2a monotherapy, pegin-
terferon a-2a plus lamivudine, or lamivudine monotherapy;
genotype, ethnicity, body weight and screening ALT were not
significant. Because ethnicity and genotype were highly
correlated and could potentially have a confounding effect on
one another, multivariate analysis was performed with ethni-
city excluded from the logistic regression model. The baseline
variables found to be significant predictors of response in the
initial model (ie, baseline HBV DNA, baseline ALT, age, gender
and type of treatment) remained significant (table 1).
In addition, genotype was also identified as a significant
predictor of combined response at 24 weeks post-treatment
(p,0.001). The odds ratios from the logistic regression analysis
indicated that a 10-fold higher baseline ALT level (ie, 500 v
50 IU/l) increased the odds of combined response 3.7-fold, and
that female patients had around twice the odds of achieving a
combined response compared with male patients. The multi-
variate analysis also confirmed that the rate of combined
response was significantly higher with peginterferon a-2a
monotherapy (p = 0.014; odds ratio (OR): 1.84) and peginter-
feron a-2a plus lamivudine (p = 0.002; OR: 2.19) than with
lamivudine, even after adjusting for the effect of the other pre-
treatment variables included in the model. Thus, those patients
treated with peginterferon a-2a (with or without lamivudine)
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had around twice the odds of achieving a combined response at
24 weeks post-treatment compared with those treated with
lamivudine monotherapy.
Of the 518 patients evaluated in the overall logistic regression
model, 400 patients had available baseline HAI scores. Using
data from these 400 patients in a separate multivariate analysis
including all prospectively defined pre-treatment variables
except ethnicity, baseline HAI score was not a significant
predictor of combined response at 24 weeks post-treatment
(p = 0.936).
Stratified analysis by significantly predictive factors
As shown in fig 1A, rates of combined response tended to be
higher in patients with higher baseline ALT levels, regardless of
treatment. The influence of baseline ALT on combined response
was particularly noticeable in the two peginterferon a-2a-
containing arms, with a combined response occurring in almost
half of the patients with ALT values .56ULN. While HBV DNA
was a significant predictor in the multivariate analysis, baseline
HBV DNA was not a significant predictor by univariate analysis
(p = 0.088) (fig 1B). Female and male patients responded
equally well to peginterferon a-2a monotherapy (fig 1C).
However, in the combination therapy and lamivudine mono-
therapy arms, combined response rates were higher in female
patients than in male patients. Patients under 40 years of age
had higher combined response rates than patients over 40 years
of age, regardless of which treatment they received (fig 1D).
Patients treated with peginterferon a-2a (with or without
lamivudine) achieved higher rates of combined response than
patients treated with lamivudine monotherapy, irrespective of
baseline ALT, HBV DNA, gender or age.
Effect of HBV genotype on combined response at
24 weeks post-treatment
In the overall logistic regression model, genotype was identified
as a significant predictor of combined response by multivariate
analysis (p,0.001) (table 1). Furthermore, in this model, a
statistically significant interaction between treatment arm and
HBV genotype was identified (p = 0.018). This interaction
indicated that the response to treatment was not uniform
across the four HBV genotypes A, B, C and D, and that patterns
of response to the three study drugs differed according to
genotype.
When the logistic regression analysis was conducted in a
subgroup of 346 patients receiving either peginterferon a-2a
monotherapy or lamivudine monotherapy, the interaction
between treatment arm and genotype was no longer significant
(p = 0.637). This model therefore indicated that rates of
combined response were higher with peginterferon a-2a than
with lamivudine, regardless of genotype (p = 0.012; OR: 1.9;
95% CI: 1.2 to 3.2). The multivariate analysis also showed that
genotype clearly influenced response in patients treated with
peginterferon a-2a or lamivudine monotherapy, as the chance
of a combined response was greater in patients infected with
genotypes B or C versus genotype D (p,0.001; OR: 5.9; 95% CI:
2.7 to 13.1, and p,0.001; OR: 4.6; 95% CI: 2.2 to 9.5,
respectively). This finding was also reflected in stratified
analyses where patients infected with genotype D had
substantially lower rates of combined response than patients
with genotypes B or C (16% (9/55) v 44% (19/43) and 49% (31/
63) with peginterferon a-2a; 11% (7/63) v 39% (19/49) and 26%
(15/57) with lamivudine, respectively).
When the multivariate model was conducted in 342 patients
treated with peginterferon a-2a monotherapy or peginterferon
plus lamivudine, the interaction between treatment arm and
genotype remained significant (p = 0.027). This interaction
occurred because of a different pattern of response to the two
peginterferon a-2a regimens among patients infected with
genotypes B or D (fig 2); in patients with genotype B the rates
of combined response were 44% for peginterferon a-2a
monotherapy and 22% for peginterferon a-2a plus lamivudine,
while in patients with genotype D the rates of combined
response were 16% for peginterferon a-2a monotherapy and
37% for peginterferon a-2a plus lamivudine. After adjusting for
the effects of gender, age, body weight, screening ALT, baseline
ALT and baseline HBV DNA, the comparison of peginterferon a-
2a plus lamivudine versus peginterferon a-2a monotherapy in
HBV genotype D infected patients resulted in an OR of 3.5 (95%
CI: 1.3 to 9.1; p = 0.015). In patients with HBV genotype B, the
same comparison resulted in an OR of 0.4 (95% CI: 0.1 to 1.2;
p = 0.097).
Factors associated with sustained virological response
and post-treatment virological relapse in patients
receiving peginterferon a-2a-containing treatment
Comparative analyses were carried out using data from 294 of
308 patients treated with peginterferon a-2a (with or without
lamivudine) who achieved a virological response (an HBV DNA
level of,20 000 copies/ml) at the end of the 48 week treatment
period; 14 patients of non-Asian or non-Caucasian origin and/
or not singularly infected with HBV genotype A, B, C or D were
excluded from the analyses. In total, 139 (47%) of these 294
patients had a sustained HBV DNA level of ,20 000 copies/ml
at 24 weeks post-treatment; the remaining 155 patients had an
HBV DNA level of .20 000 copies/ml at 24 weeks post-
treatment and were considered to have had a virological
relapse. Table 2 shows pre-treatment and on-treatment
characteristics for patients with a sustained virological response
versus those with virological relapse. Logistic regression showed
that patient age, HBV genotype and HBV DNA level at the end
of treatment (week 48) were significantly associated with post-
treatment durability of response by univariate analysis. In the
multivariate analysis, age, baseline and end-of-treatment viral
Table 1 Logistic regression analysis on pre-treatment
factors and sustained combined response*
Pre-treatment
factor Comparison
Odds ratio`
(95% CI) p Value
Age 10 year decrease 1.26 (1.0 to 1.5) 0.018
Gender Female v male 1.93 (1.1 to 3.4) 0.022
Body weight 10 kg increase 1.10 (0.9 to 1.3) 0.273
Baseline ALT 1 log10 unit (IU/l) 3.69 (1.7 to 8.1) 0.001
increase
HBV DNA 1 log10 unit 1.28 (1.1 to 1.4) ,0.001
(copies/ml) decrease
HBV genotype ,0.001
A v B 0.42 (0.1 to 1.2) 0.097
A v C 0.33 (0.1 to 0.9) 0.030
A v D 0.97 (0.3 to 2.7) 0.958
B v C 0.79 (0.5 to 1.3) 0.344
B v D 2.31 (1.3 to 4.2) 0.006
C v D 2.9 (1.7 to 5.0) ,0.001
Treatment PEG-IFNa-2a v LAM 1.84 (1.1 to 3.0) 0.014
PEG-IFNa-2a+LAM 2.19 (1.3 to 3.6) 0.002
v LAM
PEG-IFNa-2a v 1.19 (0.8 to 1.9) 0.460
PEG-IFNa-2a+LAM
Treatment by – – 0.018
HBV genotype
interaction
Multivariate analyses of all treatment arms (n = 518). LAM, lamivudine;
PEG-IFNa-2a, peginterferon a-2a; v, versus.
*Combined ALT normalisation and an HBV DNA level of ,20 000 copies/
ml after 48 weeks of treatment and 24 weeks of treatment-free follow-up;
ALT at screening was included in the model but was not a significant
predictor of response (p = 0.952); `each odds ratio adjusted for other
variables in the model.
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load, and HBV genotype were the only factors significantly
influencing post-treatment durability of response. This means
that a sustained virological response to peginterferon a-2a
(with or without lamivudine) was more likely in younger
patients (p,0.024; OR: 1.3 per 10 year decrease; 95% CI: 1.0 to
1.7), patients with lower baseline HBV DNA levels (p,0.01;
OR: 1.2 per 1 log decrease; 95% CI: 1.0 to 1.4), and patients with
lower end-of-treatment HBV DNA levels (p,0.029; OR: 2.9 per
1 log decrease; 95% CI: 1.1 to 7.7). In addition, the multivariate
analysis showed that genotype C infected patients had a higher
chance of a sustained virological response after peginterferon a-
2a (with or without lamivudine) therapy than genotype D
infected patients (p,0.001; OR: 3.3; 95% CI: 1.7 to 6.5).
Effect of pre-treatment factors on combined response at
1 year post-treatment (data from the long-term follow-
up study)
In total, 304 of the original 537 patients (57%) analysed in the
initial study participated in the roll-over observational study to
assess the durability of response to treatment, including 111
(63%) of those originally treated with peginterferon a-2a
monotherapy, 111 (62%) of those treated with peginterferon
a-2a plus lamivudine, and 82 (45%) of those treated with
lamivudine alone.27
As with the patients analysed at 24 weeks post-treatment,
only those infected with HBV genotypes A, B, C and D were
included in the analysis at the later time of assessment. The
rates of combined response observed at 1 year post-treatment
were similar to those measured at 24 weeks post-treatment in
all three treatment groups who participated in the long-term
study. The proportion of patients achieving an HBV DNA level
Figure 1 Combined response (ALT normalisation and an HBV DNA level of ,20 000 copies/ml) at 24 weeks post-treatment by baseline ALT (A), HBV
DNA (B), gender (C) and age (D). Vertical bars represent 95% CI.
Figure 2 Combined response (ALT normalisation and an HBV DNA level
of ,20 000 copies/ml) at 24 weeks post-treatment by HBV genotype in
patients treated with peginterferon a-2a monotherapy, peginterferon a-2a
plus lamivudine, or lamivudine alone. Vertical bars represent 95% CI.
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of ,20 000 copies/ml and normal ALT at 1 year post-treatment
was 33.3% (34/102; 95% CI: 24.3 to 43.4) for those originally in
the peginterferon monotherapy group, 32.7% (34/104; 95% CI:
23.8 to 42.6) for those in the peginterferon+lamivudine
combination therapy group, and 24.0% (18/75; 95% CI: 14.9
to 35.3) for those in the lamivudine group. Applying intention-
to-treat (ITT) analysis, where patients with missing data at the
1 year follow-up were deemed to be non-responders, the
response rates for the three treatment groups were 19.2% (34/
177; 95% CI: 13.1 to 25.3), 19.0% (34/179; 95% CI: 13.0 to 25.0)
and 10% (18/181; 95% CI: 5.3 to 14.6), respectively.
Data from the multivariate analysis using the original ITT
population confirmed that a combined virological and bio-
chemical response at 1 year post-treatment was more likely to
be achieved with peginterferon a-2a monotherapy (p = 0.0223;
OR 2.11) and peginterferon a-2a with lamivudine (p = 0.0185;
OR 2.16) than with lamivudine monotherapy (table 3). These
odds ratios indicated that patients treated with peginterferon a-
2a with or without lamivudine had approximately twice the
potential of achieving a combined response at 1 year post-
treatment than did those treated with lamivudine alone. In
addition, genotype was a significant predictor of response at
1 year post-treatment in logistic regression analysis. Also,
patients infected with HBV genotypes B (p = 0.0033) or C
(p,0.0001) had a better chance of achieving a combined
response at 1 year post-treatment than did genotype D infected
patients (table 3). On the other hand, age, gender, weight,
baseline ALT and baseline HBV DNA were not significant
predictors of combined response to treatment at 1 year after
treatment cessation (table 3).
DISCUSSION
The current study describes the first detailed analysis of
predictors of response in HBeAg-negative CHB. In multivariate
analyses of patients treated with peginterferon a-2a alone,
lamivudine alone, or the two in combination, high baseline
ALT, low baseline HBV DNA, younger age and female gender
were identified as significant predictors of a combined ALT and
HBV DNA response at 24 weeks post-treatment. The multi-
variate models also showed that response rates, both at
24 weeks and at 1 year post-treatment, were significantly
higher with peginterferon a-2a monotherapy than with
lamivudine monotherapy, even after adjusting for the effect
of the relevant baseline factors.
Baseline ALT levels had a strong effect on combined response
after 48 weeks of treatment and at 24 week post-treatment
follow-up, with patients in the highest baseline ALT category
(.56ULN) achieving the highest response rates, regardless of
which treatment they received. This effect was particularly
noticeable with the peginterferon a-2a-containing regimens,
with almost one half of the patients with baseline ALT
.56ULN achieving a combined response at 24 weeks post-
treatment. The effect of lower baseline HBV DNA levels on
combined response was most evident in the peginterferon a-2a
Table 2 Pre-treatment and on-treatment characteristics in patients with sustained virological
response or virological relapse
Characteristic
Sustained
virological
response
(n = 139)
Virological
relapse
(n = 155)
p Value*
(univariate)
p Value*
(multivariate)
Treatment 0.77 0.54
PEG-IFNa-2a 47% 46%
PEG-IFNa-2a+LAM 53% 54%
Age (years) 0.002 0.024
Mean¡SD 37.9¡10.6 42.0¡11.3
Gender
Male 82% 83% 0.78 0.40
Female 18% 17%
Body weight (kg) 0.14 0.36
Mean¡SD 68.7¡12.7 70.9¡13.0
Baseline HAI score 0.66 0.66
Mean¡SD 8.6¡3.5 8.8¡3.5
Baseline ALT 0.12 0.23
Mean¡SD (IU/l) 103¡96 88¡66
.56ULN 19% 15%
.2–56ULN 38% 39%
(26ULN 43% 46%
ALT level at week 48 0.59 0.36
.26ULN 15% 12%
(26ULN 85% 88%
Peak ALT level weeks 0–48 (IU/l) 0.28 0.26
Mean¡SD 51¡110 53¡69
Baseline HBV DNA (log10 copies/ml) 0.15 0.01
Mean¡SD 7.1¡2.0 7.5¡1.8
HBV DNA at week 48 0.008 0.03
(400 copies/ml 95% 83%
.400–20 000 copies/ml 5% 18%
HBV genotype ,0.001 0.006
A 4% 7%
B 24% 26%
C 50% 28%
D 21% 39%
Patients were treated with peginterferon a-2a monotherapy or peginterferon a-2a plus lamivudine. ALT, alanine
aminotransferase; HAI, Histological Activity Index; HBV, hepatitis B virus; LAM, lamivudine; PEG-IFNa-2a, peginterferon
a-2a; ULN, upper limit of normal range.
*Rates presented are actual rates for each subgroup. p Values are based on univariate or multivariate logistic regression
models; p values are from a separate logistic regression model performed on 254 patients with available baseline HAI
scores and including all other characteristics listed above.
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plus lamivudine and lamivudine monotherapy arms. Brunetto
et al have previously identified three biochemical profiles in
HBeAg-negative CHB: (i) intermittent ALT flares with inter-
vening periods of normal liver enzyme; (ii) continuous ALT
elevation without flares; and (iii) intermittent ALT flares
superimposed on continuous ALT elevation.6
The higher rate of response seen in patients with elevated
ALT at the time of treatment initiation in our study suggests
that biochemical reactivation of disease activity may be a
suitable time for starting therapy in such patients, and should
be explored further. The data indicate that in patients with
HBeAg-negative CHB and elevated ALT (with the possible
exception of those with compensated cirrhosis), treatment with
peginterferon a-2a is both efficacious and safe, provided that
the patients are carefully selected and monitored throughout
treatment.
In this study, combined response rates at 24 weeks post-
treatment were consistently higher in female patients com-
pared with male patients. This was most apparent in those
treated with combination therapy or lamivudine alone. When
combined response rates were stratified by patient age, the
highest rates were seen in younger patients, irrespective of
which treatment they received. This finding supports data from
a previous study suggesting that younger patients treated with
conventional interferon a have a higher probability of survival
compared with older patients.28
Genotype was also identified as a significant predictor of
combined response. The influence of genotype was particularly
apparent in patients treated with peginterferon a-2a or
lamivudine monotherapy, with those infected with HBV
genotype B or C having higher rates of combined response
compared with those infected with genotype D. In contrast to
the overall findings of the study, which did not document a
benefit of the combination regimen over peginterferon a-2a
monotherapy, the combination of peginterferon a-2a and
lamivudine seems to be beneficial to patients with genotype
D. Genotype D patients receiving combination therapy had
substantially higher rates of combined response than genotype
D patients receiving peginterferon a-2a monotherapy. This
apparent benefit of the combination regimen versus peginter-
feron a-2a monotherapy was not seen in patients infected with
the other genotypes. However, this observation agrees with
those of a recently published study by Colombatto et al29 where
bio-mathematical modelling revealed a greater reduction in
HBV-infected cells at the end of therapy among patients with
genotype D who were receiving combination therapy.
Since only a small number of patients infected with genotype
D participated in the long-term section of the study, it was not
possible to confirm the benefits of the combination regimen in
this subgroup of patients at the 1 year post-treatment time
point. In summary, as these findings are based on relatively few
patients and could be the result of random variation, additional
comparative data are required to confirm if combination
therapy is beneficial in the subset of HBeAg-negative CHB
patients specifically infected with HBV genotype D.
Analysis of the subset of patients who achieved a virological
response (an HBV DNA level of ,20 000 copies/ml) at the end
of treatment with peginterferon a-2a (with or without
lamivudine) revealed that older patients and those with higher
baseline and/or end-of-treatment HBV DNA levels were more
likely to experience relapse than younger patients or those with
lower HBV DNA levels. Our finding that higher baseline and
end-of-treatment HBV DNA levels were associated with relapse
concurs with previous studies of conventional interferon alone
or in combination with lamivudine.9 30 In these patients with
virological response at the end of treatment, HBV genotype was
also seen to influence the durability of response to peginter-
feron a-2a-containing therapy with patients infected with HBV
genotype D more likely to relapse post-treatment than genotype
C infected patients.
One of the limitations of our study is that predictor analysis
using the entire study population was only possible based on
efficacy outcomes assessed at 24 weeks post-treatment. An
analysis of the efficacy results at 1 year post-treatment was
based on a subgroup of patients participating in the long-term
study, and those not participating were regarded as non-
responders. For this reason, it cannot be ruled out that a
selection bias might have affected the results seen in this
subpopulation at this time point post-treatment.
In conclusion, the current analyses show that baseline ALT
and HBV DNA levels, as well as patient age and gender, are
factors which might influence post-treatment response. HBV
genotype emerges as a new predictive factor in HBeAg-negative
CHB, with genotype D being associated with a poorer response
to treatment than other genotypes. With verification in future
trials, these data on predictors of sustained response in patients
with HBeAg-negative CHB may prove useful in clinical practice
by allowing the selection of the most appropriate treatment
strategy based on individual patient characteristics. The role of
HBV genotype in tailoring treatment regimens deserves further
investigation.
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